1	Thro	mboembolic risk in hospitalised and non-hospitalised Covid-19 patients: A self-					
2		controlled case series analysis of a nation-wide cohort					
3							
4	Frederick K Ho <sup>1</sup> , Kenneth KS Man <sup>2,3</sup> , Mark Toshner <sup>4</sup> , Colin Church <sup>5</sup> , Carlos Celis-						
5		Morales <sup>6</sup> , Ian CK Wong <sup>2,3</sup> , Colin Berry <sup>6</sup> , Naveed Sattar <sup>6</sup> *, Jill P Pell <sup>1</sup> *					
6							
7	1.	Institute of Health and Wellbeing, University of Glasgow					
8	2.	School of Pharmacy, University College London					
9	3.	Centre for Safe Medication Practice and Research, Department of Pharmacy					
10		and Pharmacology, University of Hong Kong					
11	4.	Department of Medicine, School of Clinical Medicine, University of Cambridge					
12	5.	NHS Greater Glasgow and Clyde					
13	6.	Institute of Cardiovascular & Medical Sciences, University of Glasgow					
14							
15	*Joint senior authors						
16							
17	Address correspondence to:						
18							
19	Frederick K Ho, PhD ( <u>Frederick.Ho@glasgow.ac.uk)</u>						
20	Institute of Health and Wellbeing						
21	University of Glasgow						
22	1 Lilybank Gardens						
23	Glasg	ow G12 8RZ					
24	United	d Kingdom					
25							

#### 26 Abstract

27

28 **Objective:** An unexpectedly large number of people infected with Covid-19 had 29 experienced a thrombotic event. This study aims to assess the associations between 30 Covid-19 infection and thromboembolism including myocardial infarction (MI), 31 ischaemic stroke, deep-vein thrombosis (DVT), and pulmonary embolism (PE). 32 33 Patients and Methods: A self-controlled case-series study was conducted covering 34 the whole of Scotland's general population. The study population comprised 35 individuals with confirmed (positive test) Covid-19 and at least one thromboembolic 36 event between March 2018 and October 2020. Their incidence rates during the risk 37 interval (5 days before to 56 days after the positive test) and the control interval (the 38 remaining periods) were compared intra-personally. 39 40 **Results:** Across Scotland, 1,449 individuals tested positive for Covid-19 and 41 experienced a thromboembolic event. The risk of thromboembolism was significantly 42 elevated over the whole risk period but highest in the 7 days following the positive 43 test (IRR 12.01, 95% CI 9.91-14.56) in all included individuals. The association was 44 also present in individuals not originally hospitalised for Covid-19 (IRR 4.07, 95% CI 45 2.83-5.85). Risk of MI, stroke, PE and DVT were all significantly higher in the week 46 following a positive test. The risk of PE and DVT was particularly high and remained 47 significantly elevated even 56 days following the test. 48

49 **Conclusion**: Confirmed Covid-19 infection was associated with early elevations in
50 risk with MI, ischaemic stroke, and substantially stronger and prolonged elevations

- 51 with DVT and PE both in hospital and community settings. Clinicians should consider
- 52 thromboembolism, especially PE, among people with Covid-19 in the community.

- 54 **Keywords**: Covid-19; thromboembolism; stroke
- 55

#### 56 Introduction

57

Increasing evidence suggests a potential link between Covid-19 infection and
thromboembolism, which could affect a range of organs resulting in: myocardial
infarction (MI), ischaemic stroke, pulmonary embolism (PE), and deep vein
thrombosis (DVT).

62

63 First indications of a potential link came from a case report that described pulmonary 64 embolism in a patient infected with Covid-19 who had no relevant risk factors or past 65 medical history.<sup>2</sup> Subsequently hospital-based case series supported the hypothesis, 66 including ischaemic stroke in five younger (33-49 years) patients who tested positive for Covid-19.<sup>3</sup> A recent meta-analysis of 3,487 Covid-19 patients from 30 studies 67 68 produced a 26% pooled incidence of VTE, but concluded that the existing evidence was low-quality and heterogeneous.<sup>5</sup> Similar findings were reported by another 69 meta-analysis focused on PE and DVT.<sup>6</sup> VTE has now been recognised as a 70 71 relatively common complication of Covid-19 and clinical guidelines recommend the 72 use of pharmacological prophylaxis following risk assessment.<sup>7</sup> However, clinical 73 trials have provided heterogenous findings, potentially depending on the severity of 74 Covid-19.<sup>8,9</sup>

75

The current evidence, however, is mainly based on crude incidence from
hospitalised case series. Since hospitalised patients are a highly-selected minority of
those infected with Covid-19, these studies are unrepresentative and not
generalisable to the general population.<sup>10</sup> It is unknown whether people who are
asymptomatic or with mild Covid-19 symptoms (non-hospitalised) were also at a

81	higher risk of thromboembolic events. Even in studies comparing thromboembolic
82	risk between individuals with and without Covid-19 <sup>11</sup> , unobserved confounding is still
83	a major concern. To address these limitations, we conducted a self-controlled case
84	series study (SCCS) using a national, general population cohort. This method
85	overcomes bias due to unobserved health conditions. Because SCCS is conducted
86	only amount people with any thromboembolic events, we conducted a
87	supplementary cohort analysis to verify the findings.
88	
89	
90	Methods
91	
92	Data sources
93	
94	We undertook individual-level record linkage of five health databases covering the
95	whole of Scotland (5.5 million population) between March 2018 and October 2020:
96	The Community Health Index (CHI) register; Electronic Communication of
97	Surveillance in Scotland (ECOSS); Rapid Preliminary Inpatient Data (RAPID);
98	Scottish Morbidity Record 01 (SMR01), and death certificates.
99	
100	The CHI register provides sociodemographic information (age, sex, area
101	socioeconomic deprivation). Deprivation is measured using the Scottish Index of
102	Multiple Deprivation (SIMD), derived from seven domains – income, education,
103	health, employment, crime, housing, and access to services - and categorised into
104	general population quintiles. ECOSS collects laboratory data on infectious diseases,
105	including test date and result. RAPID collects real-time data on hospitalisation,

106	including dates of admission and discharge, and type of ward, and SMR01 records
107	diseases using International Classification of Diseases (ICD-10) codes and
108	procedures using Office of Population Censuses and Surveys (OPCS-4) codes.
109	Death certificates provide the date and cause (using ICD-10) of all deaths, whether
110	in hospital or the community. The Community Health Index (CHI), a unique identifier,
111	is used across all databases enabling exact matching. We extracted records
112	covering 1 March 2018 to 5 October 2020 inclusive for all databases except the
113	ECOSS Covid-19 test data which covered 1 March 2020 to 5 October 2020. The
114	Scottish data were accessed through the eDRIS, Public Health Scotland and have
115	been utilised in several previous epidemiological studies. <sup>12,13</sup> Approval for the study
116	was provided by the Public Benefit and Privacy Panel for Health and Social Care
117	(reference 2021-0064).
118	

119 In the supplementary cohort analysis, all individuals with a Covid-19 test positive

120 were included as the exposed group. For each exposed individual, 10 age-, sex-,

121 and deprivation-matched individuals who did not have a test positive were included

122 using probability density matching.

123

124 Outcomes

125

126 This study included five outcomes ascertained from SMR01 and death certificates:

127 myocardial infarction (MI; ICD-10: I21), ischaemic stroke (I63-64), pulmonary

128 embolism (PE; I26), and deep-vein thrombosis (DVT; I80.1-80.9, I82.8, I82.9), as

129 well as thromboembolism (composite of all four). To test the specificity of any

130 association between Covid-19 and thromboembolism, we also included a composite

- negative control outcome of elective surgery for hernia repair (OPCS-4 T19, T21-27),
- 132 colonoscopy (OPCS-4 H22, H25, H28), cataract surgery (OPCS-4 C71-75, C77,
- 133 C79), or hip/knee replacement (OPCS-4 W37-42, W93-95, O18).
- 134

135 Statistical Analyses

136

137 The self-controlled case series (SCCS) method was chosen to analyse the

- 138 association between Covid-19 infection and outcomes (Supplementary Figure 1), in
- 139 favour of a traditional cohort approach, because of its ability to control for
- 140 intrapersonal time-invariant confounders, and the UK's testing strategy. Frail
- 141 individuals with long-term conditions were more likely both to be tested and

142 experience adverse outcomes. These confounders may not be well recorded in the

- routine data. With a new condition, such as Covid-19, other unknown confounders
- 144 may also exist. The SCCS method eliminates intrapersonal time-invariant
- 145 confounders because each person acts as their own control.<sup>14</sup> The method has been
- 146 widely-used in epidemiological studies, including influenza and myocardial

147 infarction.<sup>15</sup>

148

149 The study population comprised everyone in Scotland who had confirmed (positive

150 real-time PCR test) Covid-19 infection and had experienced one or more

151 thromboembolic event over the study period. The incidence rate ratio (IRR) of

thromboembolic outcomes was derived from the ratio of incidence rates in risk and

- 153 control intervals. The risk interval was defined as between 5 days before and 54
- days after the sample was taken for their first positive Covid-19 test. The risk interval
- 155 was categorised into: 5 to 1 day before; 0 to 7 days after; 8 to 28 days after; and 29

to 56 days after. The five days prior to confirmed infection were included in the risk
period to take account of lags in symptom development and testing. The control
interval was defined as the remaining study period. Because the UK Covid-19
pandemic started in March 2020, the majority of the control interval occurred prior to
infection.

161

162 Conditional Poisson regression was used adjusting for participant age in quintile

163 groups, the main time-varying confounder. Deriving rates for both the risk and control

164 intervals from the same individual obviated the need to control statistically for time-

165 invariant confounders. Because individuals who had fatal events prior to the

166 pandemic had not had a chance for Covid-19 test, standard SCCS cannot be applied

167 to fatal events, and the models were run initially for non-fatal hospitalisations. We

then repeated the analyses for the composite outcome of hospitalisation or death

169 using the extended SCCS for event-dependent observation periods, which was

170 described elsewhere.<sup>16</sup>

171

172 Subgroup analyses were conducted by Covid-19 admission (those with Covid-19 as 173 primary diagnosis versus those without), age ( $\leq$ 75 versus >75 years), sex, and 174 socioeconomic deprivation (SIMD quintile 1-3 versus SIMD quintile 4-5). P-values for 175 subgroup differences were calculated. Additional subgroup analysis was conducted 176 for age (≤65, 66-80, >80 years) to explore any age trends, even though the number 177 of events were not sufficient to conduct formal tests. Three sensitivity analyses were 178 conducted. Firstly, seasonality, in three-month categories, were adjusted because 179 cardiovascular diseases exhibit seasonal patterning. Secondly, we included an 180 extended risk interval, 14 to 6 days prior to a positive test. If the elevated risk in this

181 extended interval is lower than that in the immediate pre-test interval, reverse 182 causation is less likely. Thirdly, as Covid-19 infection was not tested prior to the 2020 183 pandemic, we restricted the analysis to cases with events after 1 February 2020. 184 Lastly, we calculated the E-values to investigate how robust our findings are regarding time-varying confounders.<sup>17</sup> A high E-value suggest that only strong time-185 186 varying confounder could nullify the findings. 187 188 A supplementary cohort analysis was conducted. Time-to-event (from test positive in 189 the exposed individual) to the thromboembolic events was regressed by Covid-19 190 test positive, controlling for age, sex, and deprivation using Cox proportional hazard 191 model. Proportional hazard assumptions were checked using the Schoenfeld 192 residuals. All analyses were conducted in R version 3.5.1 with the packages SCCS 193 and survival. 194 195 Results 196 197 Of the 30,709 individuals who had at least one positive Covid-19 test (Figure 1) 198 between 1 March 2020 and 5 October 2020, the incidence rates were 44.0, 67.0, 199 48.6, 18.8 per 1,000 person-years for MI, ischaemic stroke, PE, and DVT

200 respectively. Ths SCCS analysis further excluded 29,260 individuals because they

did not have thromboembolic events in the study period. Of the 1,449 individuals

who had thromboembolic events, 117 died out-of-hospital, 81 died in-hospital and

- 203 1,251 had non-fatal events. Less than one-third (31.5%) of the individuals had a
- 204 Covid-19 primary diagnosis in hospital. Among people with non-fatal events, the
- 205 median age were 77 years (interquartile range [IQR] 65-85 years), half were male,

and 26.46% lived in the most deprived quintile (Table 1). Median age was older for

207 ischaemic stroke (82 years) and younger for PE (71 years) and DVT (73 years).

208 Women accounted for a higher percentage (58.6%) of those with DVT.

209

210 The risk of non-fatal thromboembolism was significantly higher over the whole risk

interval and highest within the seven days following the positive test (IRR 12.01, 95%

212 CI 9.91-14.56) (Table 2). The associations were strongest for PE followed by DVT

213 (Figure 2); which had similar risk patterns to overall thromboembolism. The

214 associations with MI and ischaemic stroke were smaller in magnitude but

215 nonetheless significant in the 7 days following a positive test, as well as the previous

216 5 days for MI only. Except for MI, all IRRs in the seven-day post-test interval were

217 significantly stronger than those in the pre-test intervals (Ps < 0.04). As expected,

there was no significant change in the risk of elective surgery before or after a

219 positive Covid-19 test. The findings for the composite outcome of fatal and non-fatal

220 thromboembolism were similar to those for non-fatal thromboembolism, after

accounting for censoring.

222

Adjusting for seasonality did not alter the findings (Supplementary Table 1). The extended pre-test risk interval generally had lower IRRs than the immediate pre-test interval, and were non-significant for MI, ischaemic stroke, and PE. Including only participants with thromboembolic events after February 2020 resulted in similar IRR estimates. The E-values ranged from 5.53 (MI) to 40.59 (PE) for the lower bound of 95% CIs within seven days of a positive test (Supplementary Table 2).

229

230 On subgroup analysis, the associations between a test positive and 231 thromboembolism were significant regardless of Covid-19 admission, even though 232 the elevation of risk was stronger among those admitted for Covid-19 (Table 3). A 233 positive Covid-19 test was also associated with higher risk of thromboembolism 234 regardless of age, but the magnitude of risk was significantly higher (Pinteraction 235 <0.0001) in people younger than 75 years. Compared with people aged older than 236 75 years, those younger had 23 and 47 times higher elevated thromboembolism and 237 PE risk, respectively, within seven days of a positive Covid-19 test (Table 3). There 238 appears to be a dose-response trend by age even though insufficient sample size 239 inhibited formal testing (Supplementary Table 2). A positive Covid-19 test was 240 associated with higher risk of overall thromboembolism, PE and DVT in both women 241 and men, but the magnitude of risk was higher in men (Pinteraction < 0.006). The 242 association between a positive Covid-19 test and ischaemic stroke was significant in 243 men only. There was no consistent evidence of socioeconomic deprivation being an 244 effect modifier (Supplementary Table 3). 245 246 The findings from cohort analysis were consistent with those from SCCS 247 (Supplementary Table 4). Individuals who had a Covid-19 infection was at a higher 248 risk of all of the outcomes, with strongest association with PE (HR 24.04, 95% CI 249 18.49-31.33), followed by DVT (HR 10.45, 95% CI 7.02-15.56), ischaemic stroke

250 (HR 4.40, 95% CI 3.44-5.63), and MI (HR 3.31, 95% CI 2.59-4.22).

251

252

253

### 254 Discussion

255

256	In this national, general population study including hospitalised and community-
257	dwelling individuals, we demonstrated an elevated risk of thromboembolism in
258	temporal proximity to confirmed Covid-19 infection. In the week following a positive
259	test, participants were at significantly increased risk of MI, ischaemic stroke, PE and
260	DVT, with the increased risk of the latter two being marked (Day 0 to +7 IRRs of >27
261	and >17-fold, respectively) - with risk ratios substantially exceeding those previously
262	associated with upper respiratory infections $^{18}$ – and elevated risk continuing for some
263	time thereafter. The risk ratios were even higher in younger people and in men. The
264	clear implication of this work is that PE/DVT risks are substantially elevated in
265	hospitalised patients as compared to more modest and shorter atherothrombotic
266	risks. However, there appears a broader thrombotic impact not confined to
267	hospitalised populations, albeit at a lower risk level.
268	
269	It is worth noting that the associations were also significant in individuals not
270	hospitalised for Covid-19. Although the IRRs were modest compared with the
271	hospitalised group, the excess risk for PE was sustained at near three-fold for more
272	than 1-2 months after the initial Covid-19 infection. This modest excess risk may also
273	be applicable to a large number of people who were infected with Covid-19 but not
274	hospitalised, which could mean a sizeable population burden. The annual incidence
275	of PE in the UK general population was 0.98 per 1,000 <sup>19</sup> . If the IRR on this study

- 276 (3.92 in the first 7 days of non-hospitalised group) is applicable to the general
- population, this would translate to a rate difference of 3.84 in 1,000. There were 4.27

278 million people who tested positive for Covid-19 in the UK as of 16 March 2021,

indicating that at least 16,400 new PE cases could have been caused by Covid-19.

280

281 At the present time, unpublished results from ICU Covid-19 populations have led to 282 early stopping of anticoagulant therapeutic arms because of signals suggestive of harm.<sup>8</sup> Conversely the same collated international studies have intimated a 283 284 significant decreased need for life support and improved results from less severe hospitalised patients.<sup>9</sup> Such heterogenous results could be related to the severity of 285 286 Covid-19, as well as the timing of administering pharmacologic prophylaxis. Given 287 the potentially treatable nature of thrombotic events, urgent work needs to be 288 considered in prevention and treatment trial design to consider risk stratification 289 strategy that includes Covid-19 severity, age, and sex.

290

291 Our new findings are in line but meaningfully extend previous Covid-19 studies, including another national cohort from Danmark<sup>11</sup>. A meta-analysis of over 100,000 292 Covid-19 patients reported that 1.2% developed ischaemic stroke;<sup>20</sup> a large 293 294 proportion even considering their age and vascular risk profile. A hospital-based 295 case-control study of 123 patients found an association (odds ratio 3.9) between 296 Covid-19 infection and acute ischemic stroke, after controlling for age, sex, and 297 vascular risk factors.<sup>21</sup> Similarly, two meta-analyses reported high rates of PE and 298 DVT in patients with Covid-19.<sup>5,6</sup> Of note, traditional thromboembolic risk factors 299 were not significantly associated with PE in Covid-19 patients suggesting the pathways may be different.<sup>22</sup> It should also be noted that previous studies<sup>23</sup> have 300 301 shown that the PE found in severe Covid-19 patients might actually be primarily

302 caused by pulmonary thrombi rather than pulmonary emboli, which warrants further 303 investigation.

304

305	This study's association pattern for MI is similar to that for influenza, with 5-6 times
306	higher risk in the first 7 days after a test positive. <sup>15</sup> However, the association of
307	Covid-19 with VTE appeared to be much stronger than that of other infections. For
308	example, a study using the same SCCS method found the elevated risk of DVT was
309	much lower (IRR 1.91 in the first 2 weeks) for upper respiratory infections. <sup>18</sup> The
310	same study also found that the risk of PE elevated (IRR 2.11 in the first 4 weeks)
311	following urinary tract infection. These suggest that Covid-19 may have either
312	different mechanisms, or a stronger systemic inflammation (in keeping with the
313	cytokine storm), leading to an exponential difference in the risk of PE/DVT compared
314	to other infections, while having similar elevation in MI risk.
315	
316	Our study demonstrated that the association with ischaemic stroke was significantly
317	stronger in younger (≤75 years) individuals. This is consistent with previous reports
318	of relatively young people (mean age 53-60 years) with Covid-19 requiring
319	thrombectomy. <sup>24-26</sup> In addition, among stroke patients, those who tested positive for
320	Covid-19 were on average 7-15 years younger than those tested negative. <sup>27,28</sup> The
321	underlying mechanism warrants further investigation but could relate to cytokine
322	storm, at least in some people. <sup>29</sup> Historical reports showed healthy young people
323	were more likely to experience cytokine storm following viral infections. <sup>29</sup> and

324 cytokine storm in Covid-19 patients leading to hypercoagulable was a hypothesised

mechanism for thromboembolism.<sup>30</sup> The finding that Covid-19 is associated with a 325

326 higher risk of thromboembolism in men than women may partially explain our

327 previous finding that men have worse case-fatality following Covid-19 infection.<sup>31</sup>

328 This hypothesis requires further study.

329

330 Our study has several strengths. Firstly, it was unselective; covering the whole of 331 Scotland and all confirmed Covid-19 cases regardless of whether they were 332 hospitalised. This avoided the selection bias intrinsic to hospital-based studies. Since 333 both Covid-19 infection and thromboembolism increase the chance of hospitalisation, selecting only hospital cases inevitably results in collider bias.<sup>10</sup> Secondly, time-334 335 invariant confounders, including unknown and unmeasured confounders, were 336 perfectly controlled by using participants as their own controls., The key time-varying confounders, age and seasonality, were adjusted for in the model.<sup>14</sup> The use of E-337 338 values showed that the elevated risk within seven days of test positive would only be 339 meaningfully nullified if there were very strong time-varying confounders that could 340 increase/decrease the risk of test positive and thromboembolic events by 5 to 20 341 times. Thirdly, we were able to separately analyse non-fatal events, using the 342 standard SCCS method, and all events, using a specific method designed for 343 censored data,<sup>16</sup> and the two approaches produced consistent findings. This, along 344 with the sensitivity analysis including only events shortly before the Covid-19 345 pandemic, suggest the results should be robust against immortal time biases. 346 347 However, the findings of this study are still subject to the following limitations. To

ensure internal validity, this study opted for the SCCS method, which only included
patients with at least one thromboembolism during the study period. This may limit
the generalisability of the findings to people with lower risk of these events even
though our confirmatory cohort analysis showed similar results. It should be noted

352 that, if the elevated risk of PE is truly causal, the estimates that we provided could be 353 an underestimate. The IRR for the latest categories in the risk interval was still 354 significantly greater than one, suggesting a long tail of risk elevation and thus some 355 of the pre- and post-infection control interval could be misspecified. Patients with no 356 or mild symptoms from Covid-19 infection are less likely to have been tested, 357 especially at the beginning of the pandemic when testing capacity was lower. The 358 increased risk of thromboembolism demonstrated in the days prior to confirmed 359 infection is likely to reflect the time lag between actual date of infection and our proxy 360 measure of it; date of specimen collection. Reverse causation is possible in some 361 patients; for example, nosocomial infection of patients hospitalised for 362 thromboembolic events. However, the lack of an association with elective surgery 363 suggests that any reverse causation is unlikely to fully explain our findings. The 364 lowered risk in extended pre-test interval for outcomes except MI also does not 365 support strong reverse causation. It is highly likely that there was underreporting of 366 events from the first wave. There were 1465 individuals who died of suspected 367 Covid-19 (ICD-10: U07.2) without any tests suggesting individuals who had Covid-19 368 but untested is only a small proportion (4.8%) compared to those tested and unlikely 369 to change our conclusion. Even though there was no role for routine CT scanning in Covid-19<sup>32</sup> and data on rates of advanced imaging are not yet clear, it is our 370 371 expectation that more extensive imaging in subsequent waves is highly likely to 372 increase pick-up of thrombus. 373

In conclusion, Covid-19 infection was associated with substantially elevated risk of
PE and DVT, with excess PE risk lasting at least 8 weeks post-infection. These

376 complications should be addressed through prophylaxis and early detection;

- 377 clinicians should be alerted to the possibility of PEs in community treated patients
- 378 with residual or prolonged symptoms. Clinical trials to prevent thrombotic events

379 should consider the post-hospital convalescent stage where we have demonstrated

- 380 ongoing increased risk in addition to younger individuals with Covid-19.
- 381

## 382 Acknowledgements

383

This study was supported by the Wellcome Trust ISSF COVID Response Fund in the University of Glasgow. The authors would like to acknowledge the support of the eDRIS Team (Public Health Scotland), especially Ms Johanna Bruce, for their involvement in obtaining approvals, provisioning and linking data and the use of the secure analytical platform within the National Safe Haven.

- 389
- 390

# 391 References

- Johns Hopkins University & Medicine. Coronavirus Resource Center.
   https://coronavirus.jhu.edu/. Published 2021. Accessed.
- Danzi GB, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? *European heart journal.* 2020;41(19):1858-1858.
- Oxley TJ, Mocco J, Majidi S, et al. Large-vessel stroke as a presenting feature
   of Covid-19 in the young. *New England Journal of Medicine*.
   2020;382(20):e60.
- 400 4. Klok F, Kruip M, Van der Meer N, et al. Incidence of thrombotic complications 401 in critically ill ICU patients with COVID-19. *Thrombosis research.* 2020.
- 402 5. Porfidia A, Valeriani E, Pola R, Porreca E, Rutjes AW, Di Nisio M. Venous
  403 thromboembolism in patients with COVID-19: Systematic review and meta404 analysis. *Thrombosis research.* 2020;196:67-74.
- 405 6. Suh YJ, Hong H, Ohana M, et al. Pulmonary Embolism and Deep Vein
  406 Thrombosis in COVID-19: A Systematic Review and Meta-Analysis.
  407 Radiology. 2020:203557.
- 408 7. NICE. COVID-19 rapid guideline: reducing the risk of venous
  409 thromboembolism in over 16s with COVID-19. NICE guideline [NG186] Web
  410 site. <u>https://www.nice.org.uk/guidance/ng186</u>. Published 2020. Accessed 13
  411 January, 2021.
- 8. Statement from the REMAP-CAP trial on blood thinners in COVID-19 patients[press release]. 2020.
- 414 9. Full-dose blood thinners decreased need for life support and improved
  415 outcome in hospitalized COVID-19 patients [press release]. 2021.
- 416 10. Griffith G, Morris TT, Tudball M, et al. Collider bias undermines our
  417 understanding of COVID-19 disease risk and severity. *Nature Communication*418 2020;11(5749).
- 419 11. Dalager-Pedersen M, Lund LC, Mariager T, et al. Venous thromboembolism
  420 and major bleeding in patients with COVID-19: A nationwide population-based

421		cohort study. Clinical infectious diseases: an official publication of the
422		Infectious Diseases Society of America. 2021.
423	12.	Mackay DF, Nelson SM, Haw SJ, Pell JP. Impact of Scotland's smoke-free
424		legislation on pregnancy complications: retrospective cohort study. PLoS Med.
425		2012;9(3):e1001175.
426	13.	Turner S, Mackay D, Dick S, Semple S, Pell JP. Associations between a
427		smoke-free homes intervention and childhood admissions to hospital in
428		Scotland: an interrupted time-series analysis of whole-population data. The
429		Lancet Public Health. 2020;5(9):e493-e500.
430	14.	Whitaker HJ, Paddy Farrington C, Spiessens B, Musonda P. Tutorial in
431		biostatistics: the self-controlled case series method. Statistics in medicine.
432		2006;25(10):1768-1797.
433	15.	Kwong JC, Schwartz KL, Campitelli MA, et al. Acute myocardial infarction
434		after laboratory-confirmed influenza infection. New England Journal of
435		Medicine, 2018:378(4):345-353.
436	16.	Farrington CP. Whitaker HJ. Hocine MN. Case series analysis for censored.
437		perturbed, or curtailed post-event exposures. <i>Biostatistics</i> , 2009:10(1):3-16.
438	17.	Haneuse S. VanderWeele TJ. Arterburn D. Using the E-value to assess the
439		potential effect of unmeasured confounding in observational studies, JAMA.
440		2019:321(6):602-603.
441	18.	Smeeth L, Cook C, Thomas S, Hall AJ, Hubbard R, Vallance P, Risk of deep
442		vein thrombosis and pulmonary embolism after acute infection in a community
443		setting. The Lancet. 2006:367(9516):1075-1079.
444	19.	Kempny A. McCabe C. Dimopoulos K. et al. Incidence, mortality and bleeding
445		rates associated with pulmonary embolism in England between 1997 and
446		2015. International journal of cardiology. 2019:277:229-234.
447	20.	Nannoni S. de Groot R. Bell S. Markus HS. Stroke in COVID-19: a systematic
448		review and meta-analysis. International Journal of Stroke.
449		2020:1747493020972922.
450	21.	Belani P. Schefflein J. Kihira S. et al. COVID-19 is an independent risk factor
451		for acute ischemic stroke. American Journal of Neuroradiology.
452		2020:41(8):1361-1364.
453	22.	Fauvel C. Weizman O. Trimaille A. et al. Pulmonary embolism in COVID-19
454		patients: a French multicentre cohort study. European heart journal.
455		2020:41(32):3058-3068.
456	23.	Cattaneo M. Bertinato EM. Birocchi S. et al. Pulmonary embolism or
457	_0.	pulmonary thrombosis in COVID-19? Is the recommendation to use high-dose
458		heparin for thromboprophylaxis justified? 2020.
459	24	Wang A. Mandigo GK. Yim PD. Meyers PM. Lavine SD. Stroke and
460		mechanical thrombectomy in patients with COVID-19: technical observations
461		and patient characteristics . Journal of NeuroInterventional Surgery
462		2020·12(7)·648-653
463	25	Sweid A Hammoud B Bekelis K et al Cerebral ischemic and hemorrhagic
464	20.	complications of coronavirus disease 2019 International Journal of Stroke
465		2020-15(7)-733
466	26	Escalard S Maïer B Rediem H et al Treatment of Acute Ischemic Stroke
467	20.	due to Large Vessel Occlusion With COV/ID-10. Experience From Paris
468		Stroke 2020 STROKEAHA 120 030574
460	27	Vanhi S Ishida K Torres I at al SARS2-CoV-2 and stroke in a New York
470 170	21.	healthcare system Stroke 2020 STROKEAHA 120 030325
+/0		Healingare system. Shoke, 2020.511 OKEAHA, 120.050555.

- 471 28. Majidi S, Fifi JT, Ladner TR, et al. Emergent large vessel occlusion stroke
  472 during New York City's COVID-19 outbreak: clinical characteristics and
  473 paraclinical findings. *Stroke.* 2020;51(9):2656-2663.
- 474 29. Ma J, Dushoff J, Earn DJ. Age-specific mortality risk from pandemic influenza.
  475 Journal of theoretical biology. 2011;288:29-34.
- 476 30. Ellul M, Benjamin L, Singh B, et al. Neurological Associations of COVID-19.
  477 The Lancet Neurology. 2020;19(9):767-783.
- 478 31. Jani BD, Ho FK, Lowe DJ, et al. Comparison of COVID-19 outcomes among
  479 shielded and non-shielded populations: A general population cohort study of
  480 1.3 million. *medRxiv.* 2020.
- 481 32. The role of CT in patients suspected with COVID-19 infection [press release].482 2020.
- 483

Figure 1. Participant flowchart

Figure 2. Associations between Covid-19 and non-fatal outcomes.

IRR shown is the within incidence rate ratio for outcomes. Incidence rates in the risk period (5 days prior to 56 after a positive Covid-19 test) were compared against the control period (all remaining time in study period) for each person.

 Table 1. Patients characteristics for analysis of non-fatal admissions.

	Composite	Myocardial infarction	lschaemic stroke	Pulmonary embolism	Deep-vein thrombosis	Elective surgery*
N for all events	1449	376	560	417	179	123
N for admissions only	1332	337	505	391	174	123
N for non-fatal admissions only	1251	319	473	359	169	116
Covid-19 as primary diagnosis						
in admission episode	389 (31.5)	104 (32.6)	123 (26.0)	145 (40.4)	41 (26.6)	14 (12.1)
Median (IQR) age, years	77 (65-85)	78 (67-85)	82 (73-87)	71 (59-81)	73 (59-82)	78 (70-85)
Sex						
Female	626 (50.04)	128 (40.13)	246 (52.01)	180 (50.14)	99 (58.58)	45 (38.79)
Male	625 (49.96)	191 (59.87)	227 (47.99)	179 (49.86)	70 (41.42)	71 (61.21)
SIMD quintile						
1 <sup>st</sup> (Most deprived)	331 (26.46)	91 (28.53)	124 (26.22)	84 (23.40)	47 (27.81)	34 (29.31)
2 <sup>nd</sup>	282 (22.54)	79 (24.76)	100 (21.14)	88 (24.51)	32 (18.93)	21 (18.10)
3 <sup>rd</sup>	230 (18.39)	55 (17.24)	94 (19.87)	65 (18.11)	33 (19.53)	21 (18.10)
4 <sup>th</sup>	230 (18.39)	53 (16.61)	95 (20.08)	68 (18.94)	27 (15.98)	25 (21.55)
5 <sup>th</sup> (Least deprived)	178 (14.23)	41 (12.85)	60 (12.68)	54 (15.04)	30 (17.75)	15 (12.93)

Numbers (%) are presented unless otherwise specified. \*Elective surgery included hernia repair, colonoscopy, cataract surgery, and hip and knee replacement, and is a negative control outcome

Outcome by	Non-fatal ever	nts	All events <sup>†</sup>			
risk intervals	IRR (95% CI) P IRR (9		IRR (95% CI)	Р		
Composite						
5-1 days before	4.77 (3.20, 7.10)	<0.0001	3.71 (2.50, 5.49)	<0.0001		
0-7 days after	12.01 (9.91, 14.56)	<0.0001	5.70 (4.72, 6.89)	<0.0001		
8-28 days after	2.82 (2.16, 3.67)	<0.0001	1.54 (1.22, 1.94)	0.0003		
28-56 days after	2.30 (1.77, 3.00)	<0.0001	1.51 (1.21, 1.88)	0.0002		
Myocardial infarction						
5-1 days before	5.15 (2.54, 10.46)	<0.0001	3.79 (1.86, 7.71)	0.0002		
0-7 days after	5.16 (3.04, 8.73)	<0.0001	1.98 (1.23, 3.18)	0.005		
8-28 days after	1.51 (0.77, 2.95)	0.23	0.85 (0.50, 1.44)	0.55		
28-56 days after	1.15 (0.56, 2.35)	0.70	0.90 (0.53, 1.50)	0.67		
Ischaemic stroke						
5-1 days before	2.12 (0.88, 5.13)	0.10	1.58 (0.65, 3.84)	0.31		
0-7 days after	7.22 (5.02, 10.38)	<0.0001	3.25 (2.34, 4.50)	<0.0001		
8-28 days after	0.75 (0.35, 1.58)	0.45	0.69 (0.42, 1.12)	0.14		
28-56 days after	1.11 (0.63, 1.94)	0.72	0.94 (0.63, 1.41)	0.77		
Pulmonary embolism						
5-1 days before	9.95 (5.42, 18.27)	<0.0001	7.47 (4.13, 13.51)	<0.0001		
0-7 days after	27.55 (20.55, 36.95)	<0.0001	16.81 (12.46, 22.69)	<0.0001		
8-28 days after	7.27 (5.07, 10.43)	<0.0001	4.52 (3.21, 6.35)	<0.0001		
28-56 days after	5.59 (3.87, 8.07)	<0.0001	3.54 (2.54, 4.93)	<0.0001		
Deep vein thrombosis						
5-1 days before	4.67 (1.48, 14.72)	0.008	4.23 (1.34, 13.32)	0.01		
0-7 days after	17.44 (11.00, 27.66)	<0.0001	11.51 (7.30, 18.16)	<0.0001		
8-28 days after	3.64 (1.90, 7.01)	0.0001	2.43 (1.27, 4.67)	0.008		
28-56 days after	1.98 (0.91, 4.29)	0.08	1.77 (0.92, 3.42)	0.09		
Elective surgeries*						
5-1 days before	-	-	-	-		
0-7 days after	1.69 (0.41, 6.88)	0.47	1.28 (0.40, 4.06)	0.67		
8-28 days after	1.78 (0.65, 4.90)	0.26	0.94 (0.34, 2.59)	0.91		
28-56 days after	2.28 (0.98, 5.32)	0.06	1.19 (0.51, 2.76)	0.68		

Table 2. Associations between COVID-19 and outcomes.

Patients' age quintile was adjusted

IRR: incidence rate ratio

\*Elective surgery included hernia repair, colonoscopy, cataract surgery, and hip/knee replacement, and is a negative control outcome

<sup>†</sup>Including both fatal and non-fatal events, with event dependent observation handled using specialised method

	Covid-19 hospitalisation			Age			Sex		
Outcome by	Yes	No		≤75 years	>75 years		Female	Male	
risk intervals	IRR (95% CI)	IRR (95% CI)	Pinteraction	IRR (95% CI)	IRR (95% CI)	<b>P</b> interaction	IRR (95% CI)	IRR (95% CI)	Pinteractio
Composite				<b>,</b> , , , , , , , , , , , , , , , , , ,			<b>,</b> <i>, , ,</i>		
5-1 days before	12.45 (7.37, 21.03)	2.48 (1.33, 4.63)	0.0001	3.80 (2.44, 5.93)	2.60 (1.81, 3.72)	0.19	2.22 (1.41, 3.47)	4.31 (3.02, 6.15)	0.03
0-7 days after	36.97 (28.69, 47.64)	4.07 (2.83, 5.85)	<0.0001	22.78 (17.58, 29.53)	5.94 (4.35, 8.12)	<0.0001	6.36 (4.47, 9.04)	19.44 (15.38, 24.58)	<0.000
8-28 days after	6.16 (4.18, 9.09)	1.82 (1.26, 2.63)	<0.0001	5.79 (4.16, 8.07)	1.24 (0.78, 1.97)	<0.0001	2.64 (1.83, 3.82)	3.19 (2.18, 4.66)	0.50
28-56 days after	4.85 (3.27, 7.20)	1.50 (1.04, 2.17)	<0.0001	4.27 (3.03, 6.03)	1.12 (0.72, 1.74)	<0.0001	2.28 (1.59, 3.27)	2.46 (1.66, 3.65)	0.79
Myocardial infarction									s m
5-1 days before	3.58 (0.86, 14.88)	6.17 (2.73, 13.95)	0.52	4.14 (2.00, 8.54)	3.36 (1.80, 6.26)	0.67	4.29 (2.15, 8.58)	3.47 (1.82, 6.60)	0.66
0-7 days after	8.09 (3.87, 16.90)	3.38 (1.50, 7.65)	0.12	6.19 (2.85, 13.42)	3.65 (1.69, 7.88)	0.34	3.35 (1.22, 9.18)	6.45 (3.46, 12.00)	0.28 <sup>0</sup>
8-28 days after	1.00 (0.24, 4.17)	1.85 (0.86, 3.96)	0.46	2.49 (1.08, 5.77)	0.77 (0.24, 2.45)	0.11	1.58 (0.57, 4.39)	1.43 (0.58, 3.50)	0.89
28-56 days after	1.28 (0.39, 4.22)	1.15 (0.47, 2.81)	0.89	1.01 (0.32, 3.23)	0.97 (0.35, 2.64)	0.96	1.41 (0.51, 3.92)	0.94 (0.34, 2.57)	0.60
Ischaemic stroke									Ie
5-1 days before	3.23 (0.79, 13.30)	1.62 (0.52, 5.06)	0.45	1.70 (0.54, 5.39)	1.84 (1.00, 3.37)	1.00	1.21 (0.50, 2.96)	2.58 (1.32, 5.08)	0.18
0-7 days after	14.03 (8.11, 24.27)	4.22 (2.50, 7.12)	0.0019	17.81 (10.67, 29.72)	3.63 (2.07, 6.38)	<0.0001	2.05 (0.84, 5.00)	13.27 (8.79, 20.04)	0.000
8-28 days after	1.26 (0.39, 4.07)	0.51 (0.19, 1.37)	0.25	0.45 (0.06, 3.27)	0.81 (0.36, 1.84)	1.00	0.75 (0.28, 2.03)	0.72 (0.23, 2.26)	0.96
28-56 days after	2.37 (1.06, 5.29)	0.60 (0.27, 1.36)	0.02	1.46 (0.53, 4.02)	0.93 (0.47, 1.83)	0.47	1.20 (0.59, 2.45)	0.96 (0.39, 2.37)	0.75
Pulmonary embolism									
5-1 days before	50.25 (24.26, 104.07)	2.09 (0.52, 8.44)	0.0001	5.36 (2.60, 11.08)	3.40 (1.64, 7.03)	0.39	1.98 (0.73, 5.37)	8.10 (4.42, 14.86)	0.02
0-7 days after	135.97 (88.89, 207.98)	3.92 (1.83, 8.40)	<0.0001	46.84 (32.21, 68.12)	10.36 (5.99, 17.91)	<0.0001	15.22 (9.30, 24.90)	43.82 (29.78, 64.48)	0.001
8-28 days after	23.97 (14.03, 40.97)	3.54 (2.03, 6.16)	<0.0001	12.64 (8.20, 19.49)	2.04 (0.93, 4.48)	0.0001	5.77 (3.42, 9.71)	9.35 (5.63, 15.54)	0.20
28-56 days after	16.26 (9.35, 28.27)	2.99 (1.74, 5.15)	<0.0001	8.13 (5.16, 12.81)	1.88 (0.90, 3.94)	0.0009	4.98 (3.02, 8.21)	6.21 (3.58, 10.77)	0.57
Deep vein thrombosis									l on
5-1 days before	24.07 (5.54, 104.49)	1.82 (0.25, 13.20)	0.04	2.20 (0.54, 9.04)	3.83 (1.51, 9.69)	1.00	3.18 (1.16, 8.73)	3.90 (1.20, 12.65)	0.80
0-7 days after	92.44 (46.02, 185.68)	3.77 (1.36, 10.46)	<0.0001	24.21 (13.13, 44.64)	10.59 (5.11, 21.97)	0.09	8.04 (3.49, 18.57)	33.91 (18.80, 61.18)	0.006
8-28 days after	9.54 (3.15, 28.93)	2.75 (1.18, 6.40)	0.08	5.30 (2.38, 11.80)	1.74 (0.53, 5.68)	0.13	4.89 (2.33, 10.26)	2.03 (0.49, 8.45)	0.33
28-56 days after	1.46 (0.19, 11.55)	2.35 (1.01, 5.46)	0.67	2.85 (1.11, 7.28)	0.91 (0.22, 3.82)	0.19	1.41 (0.44, 4.50)	3.49 (1.23, 9.90)	0.26

 Table 3. Subgroup analysis for non-fatal events.

Patients' age quintile was adjusted IRR: incidence rate ratio; SIMD: Scottish Index of Multiple Deprivation



